In a genetic mouse model of pancreatic carcinoma, treatment with a Shh inhibitor, IPI-926, led to decreased desmoplasia and increased efficacy of gemcitabine [18]. This evidence concerns the gene SHH and exocrine pancreatic carcinoma.